Life Sciences Tools & Services
In Q2 FY2024, MTD delivered 4.5% year-over-year revenue growth to $1.03B and a 15.1% increase in net income to $232.9M, aided by a net $24.6M one-time tariff refund benefit alongside steady laboratory and industrial product demand.
Key risk: Global Trade Disputes and Evolving Tariff Rates
Following the invalidation of IEEPA tariffs, the U.S. instituted Section 301 tariffs on Swiss, Chinese, EU, UK, and Mexican imports. Future rate changes or potential termination of USMCA could increase cost of sales and create margin volatility.
Other Life Sciences Tools & Services companies